Thomas H. Taylor
University of California, Irvine
EpidemiologyCancerInternal medicineEthnic groupSurgeryPathologyOncologyDemographyCancer registryLymphomaAcquired immunodeficiency syndrome (AIDS)PopulationIncidence (epidemiology)Confidence intervalColorectal cancerBreast cancerClinical trialMedicineGerontologyRelative riskGastroenterology
75Publications
27H-index
2,067Citations
Publications 74
Newest
#1Christopher M. DumaH-Index: 19
Last. Robert O. DillmanH-Index: 49
view all 18 authors...
Source
#1Farshid Dayyani (UCI: University of California, Irvine)H-Index: 26
#2Chloe Thomas (UCI: University of California, Irvine)H-Index: 1
Last. Thomas H. Taylor (UCI: University of California, Irvine)H-Index: 27
view all 4 authors...
TPS253Background: GEC is the third leading cause of cancer mortality and the fifth most common malignancy worldwide. Fluoropyrimidine and platinum-based combinations are the most commonly used 1L t...
Source
#1Daniela A. Bota (UCI: University of California, Irvine)H-Index: 23
#2David Piccioni (UCSD: University of California, San Diego)H-Index: 23
Last. Robert O. DillmanH-Index: 49
view all 18 authors...
Source
#1Daniela A. Bota (UCI: University of California, Irvine)H-Index: 23
#2Thomas H. TaylorH-Index: 27
Last. Apostolos StathopoulosH-Index: 7
view all 8 authors...
Source
#1Daniela A. BotaH-Index: 23
#2David Piccioni (UCSD: University of California, San Diego)H-Index: 23
Last. Robert O. DillmanH-Index: 49
view all 13 authors...
Background Primary glioblastoma (GBM) is associated with poor survival. Adjunctive vaccines may improve survival by inducing or enhancing anti-GBM immune responses. Methods A multi-institutional phase II clinical trial was conducted with a primary objective of 75% survival 15 months after intent-to-treat enrollment. Key eligibility criteria were: (1) primary GBM diagnosis, (2) age 70 after surgical recovery. Dendritic cells (DC) were differentiated from autologous monocytes, then incubated with ...
Source
#1D. Bota (UCI: University of California, Irvine)H-Index: 1
#2Christopher M. Duma (Hoag)H-Index: 19
Last. Robert O. DillmanH-Index: 49
view all 16 authors...
Standard treatment of primary glioblastoma (GBM) is associated with poor survival. Adjunctive therapy with patient-specific vaccines may improve outcomes by inducing or enhancing each patient9s anti-GBM immune response. A multi-institutional phase II clinical trial was designed with a primary objective of 75% survival 15 months after intent-to-treat enrollment. Key eligibility criteria were: (1) primary GBM diagnosis, (2) age 70 after recovery from surgery. IL-4 and GM-CSF were used to generate ...
Source
#1Maya Hrachova (UCI: University of California, Irvine)H-Index: 2
#2Emely Nhi T. Nguyen (UCI: University of California, Irvine)H-Index: 1
Last. Daniela A. BotaH-Index: 23
view all 10 authors...
: Background: Meningiomas are the most common adult primary intracranial tumors in the United States. Despite high recurrence rate of atypical and malignant subtypes, there is no approved drug indicated specifically for meningioma. Since the majority of meningiomas exhibit high density of somatostatin receptors subtypes, somatostatin analogs have been under close investigation. The aim of this study was to evaluate efficacy and safety of Sandostatin LAR (octreotide) in patients with progressive,...
1 CitationsSource
#1Fasiha KanwalH-Index: 61
#2Thomas H. TaylorH-Index: 27
Last. Aanand D. NaikH-Index: 39
view all 8 authors...
Source
#1Daniela A. BotaH-Index: 23
#2Thomas H. TaylorH-Index: 27
Last. Apostolos StathopoulosH-Index: 7
view all 9 authors...
Source
#1Daniela A. BotaH-Index: 23
#2Thomas H. TaylorH-Index: 27
Last. Robert O. DillmanH-Index: 49
view all 12 authors...
1 CitationsSource